Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 23;218(7):e20210554. doi: 10.1084/jem.20210554

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Bastard et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 1. — APS-1 patients have neutralizing auto-Abs against type I IFNs, the titers of which can be decreased by plasmapheresis. (A) Titers of auto-Ab titers against the 17 type I IFNs in APS-1 patients infected with SARS-CoV-2 (n = 8). (B) Neutralization of IFN-α2 by various dilutions of auto-Ab–containing serum from APS-1 patients with COVID-19 (n = 5). Relative luciferase activity is shown after stimulation with 10 ng/ml of IFN-α2. Results representative of two independent experiments are shown. ISRE, IFN stimulation response element; RLU, relative light units. (C) Plasmapheresis decreased the titers of type I IFN auto-Abs in one APS-1 patient (patient 17) with COVID-19 pneumonia. The titers of auto-Abs against IFN-α2 are shown for one of the APS-1 patients treated by plasmapheresis (PE). (D) Plasmapheresis (PE) decreased the titers of type I IFN auto-Abs in another APS-1 patient (patient 18) with COVID-19 pneumonia, treated with plasmapheresis, convalescent plasma, and IFN-β (as shown with arrows). The titers of auto-Abs against IFN-α2 are shown for the APS-1 patients treated by plasmapheresis in the upper panel. In the lower panel, ISG scores (evaluated by NanoString) show an increase after the initiation of treatments. ISG score cutoff for positivity is 2,758. RQ, relative quantitation.